Has RUBICON RESEARCH had other FDA enforcement actions?

Yes. Argus HQ has recorded 4 total FDA actions tied to RUBICON RESEARCH: 0 warning letters, 0 recalls, 4 approval records, and 0 Form 483 inspection citations.

What kind of FDA record is this?

This is an Argus HQ record of a FDA Drug Approval, tagged info severity by Argus HQ. FDA published the underlying record on 2026-09-10; Argus observed and indexed it on 2026-09-16.

Where can I verify this record directly with FDA?

The verbatim FDA source record is the source of truth — Argus HQ links directly to it below. Always confirm against fda.gov before acting.

.hq

fda_approval · anda · info

RUBICON RESEARCH — ANDA approval: SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE (unspecified)

Name: FDA Drug Approval Record — RUBICON RESEARCH
Creator: Argus HQ
Published: 2026-09-10
License: https://argushq.ai/methodology

Event date: 2026-09-10 00:00:00Z
Observed: 2026-09-16 04:30:40Z
Source ID: ANDA220884-1
Payload hash: 863d616848910a6a62d63c17…

Summary

RUBICON RESEARCH received ANDA approval for SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE (unspecified) on 2026-09-10. Dosage form: TABLET. Application #: ANDA220884.

Entities

RUBICON RESEARCH

View source record ↗

Frequently asked questions

Has RUBICON RESEARCH had other FDA enforcement actions?: Yes. Argus HQ has recorded 4 total FDA actions tied to RUBICON RESEARCH: 0 warning letters, 0 recalls, 4 approval records, and 0 Form 483 inspection citations.
What kind of FDA record is this?: This is an Argus HQ record of a FDA Drug Approval, tagged info severity by Argus HQ. FDA published the underlying record on 2026-09-10; Argus observed and indexed it on 2026-09-16.
Where can I verify this record directly with FDA?: The verbatim FDA source record is the source of truth — Argus HQ links directly to it below. Always confirm against fda.gov before acting.

Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder

Cite this record

Reusing this data in reporting or research? Here’s a ready-made citation.

APA

Argus HQ Research (2026). RUBICON RESEARCH — ANDA approval: SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE (unspecified). Digital Empire Holdings LLC. Retrieved from https://argushq.ai/events/fda-approval-rubicon-research-anda220884-1

MLA

"RUBICON RESEARCH — ANDA approval: SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE (unspecified)." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/events/fda-approval-rubicon-research-anda220884-1.

Chicago

Argus HQ Research. "RUBICON RESEARCH — ANDA approval: SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE (unspecified)." Digital Empire Holdings LLC. Accessed October 14, 2026. https://argushq.ai/events/fda-approval-rubicon-research-anda220884-1.

BibTeX

@misc{argushq_argushq_ai_events_fda_approval_rubicon_research_anda220884_1_2026,
  title = {RUBICON RESEARCH — ANDA approval: SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE (unspecified)},
  author = {{Argus HQ Research}},
  year = {2026},
  publisher = {Digital Empire Holdings LLC},
  url = {https://argushq.ai/events/fda-approval-rubicon-research-anda220884-1},
  note = {Accessed: October 14, 2026}
}

Informational only. Not legal, financial, or medical advice.